Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Long-Term Deferred Tax (2020 - 2025)

Lexaria Bioscience's Long-Term Deferred Tax history spans 5 years, with the latest figure at $13.4 million for Q3 2025.

  • Quarterly results put Long-Term Deferred Tax at $13.4 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Aug 2025 was $13.4 million (changed N/A YoY), and the annual figure for FY2025 was $13.4 million, changed.
  • Long-Term Deferred Tax for Q3 2025 was $13.4 million at Lexaria Bioscience, up from $9.6 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $13.4 million in Q3 2025 to a low of $6.6 million in Q3 2021.
  • The 4-year median for Long-Term Deferred Tax is $8.7 million (2022), against an average of $9.4 million.
  • The sharpest move saw Long-Term Deferred Tax grew 18.01% in 2021, then increased 21.81% in 2023.
  • Year by year, Long-Term Deferred Tax stood at $6.6 million in 2021, then rose by 19.28% to $7.9 million in 2022, then rose by 21.81% to $9.6 million in 2023, then surged by 39.99% to $13.4 million in 2025.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $13.4 million, $9.6 million, and $7.9 million for Q3 2025, Q3 2023, and Q3 2022 respectively.